on behalf of the PRESTIGE Investigators ABSTRACT OBJECTIVES High platelet reactivity (HPR) was studied in patients presenting with ST-segment elevation myocardial infarction (STEMI) due to stent thrombosis (ST) undergoing immediate percutaneous coronary intervention (PCI).
P rior studies have shown that patients with high platelet reactivity (HPR) on treatment with the P2Y 12 inhibitor clopidogrel after percutaneous coronary intervention (PCI) are at higher risk of death, myocardial infarction, and coronary stent thrombosis (ST) during follow-up (1) . ST is a rare but severe complication of PCI. In a stable phase after ST, HPR on clopidogrel treatment has been reported in many patients (2, 3) ; however, nothing is known about the platelet reactivity and HPR rates in patients presenting with ST undergoing immediate PCI.
It can be hypothesized that the HPR rates in ST patients presenting with ST-segment elevation myocardial infarction (STEMI) might be similar as in patients with spontaneous STEMI, as around 80% of ST patients present with a myocardial infarction (4, 5) . In patients presenting with STEMI, it is known that 63% to 93% have HPR measured at the time of immediate PCI after loading with P2Y 12 inhibitors (clopidogrel, prasugrel, or ticagrelor) (6) (7) (8) (9) , and HPR after intravenously administration of aspirin in patients presenting with STEMI was observed in 6% of the patients (10). A clear difference however is that part of the ST patients are on antiplatelet therapy (APT) while developing ST, whereas spontaneous STEMI patients are not. We wonder therefore how maintenance APT while developing ST and loading with APT shortly before immediate PCI influence platelet reactivity and HPR rates in ST patients presenting with STEMI. Values are n (%) or mean AE SD.
APT ¼ antiplatelet therapy; other abbreviations as in Table 1 . P2Y 12 inhibitor, and 63 of 76 patients were on maintenance aspirin. HPR-ADP rates were no different in patients who were on maintenance therapy with a P2Y 12 inhibitor while developing ST than in those without this therapy (Figure 2A) . The number of patients was too low to differentiate between maintenance therapies with the different P2Y 12 inhibitors.
HPR-AA was also similar in patients who were on aspirin at presentation with ST compared with those who were not ( Figure 2C) . The majority of the patients who were not on maintenance therapy with a P2Y 12 inhibitor presented with very late ST (80%). inhibitors was significantly shorter in patients with HPR-ADP than in patients without HPR-ADP ( Table 3) . Figure 3 . (18, 19) . This may be exacerbated by the use of morphine, which lowers gastrointestinal uptake and is associated with higher platelet reactivity compared with patients without morphine administration (20, 21) . In addition, clopidogrel and prasugrel need conversion to the active metabolite before platelet reactivity can be inhibited. These mechanisms probably largely explain the absence of differences in HPR-ADP rates in patients who did or did not receive a loading dose.
DISCUSSION
However, because platelet response to P2Y 12 WHAT IS NEW? This study investigated for the first time the platelet reactivity in ST patients presenting with STEMI for immediate PCI, and showed that HPR rates were comparable in patients on maintenance APT or not, and similar in patients loaded with P2Y 12 inhibitors or not.
WHAT IS NEXT? Follow-up of patients treated with additional direct-acting, intravenous platelet inhibitor treatment during PCI could reveal whether this strategy will reduce the risk for (recurrent) thrombotic events.
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